Literature DB >> 19892770

Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis.

E A Yeh1, B Weinstock-Guttman, M Ramanathan, D P Ramasamy, L Willis, J L Cox, R Zivadinov.   

Abstract

The purpose of this study was to compare the clinical and quantitative magnetic resonance imaging metrics of paediatric-onset multiple sclerosis to adult-onset multiple sclerosis. It was a prospective comparison of clinical and magnetic resonance imaging characteristics of two paediatric onset multiple sclerosis and two adult onset multiple sclerosis groups that were matched for disease duration. The paediatric-onset-C group consisted of children with paediatric-onset multiple sclerosis with mean disease duration of 2.7 years, whereas the paediatric onset-A group consisted of adults with mean disease duration of 20 years. The adult onset multiple sclerosis-1 and adult onset multiple sclerosis-2 groups were matched to the paediatric onset-C and paediatric onset-A groups. The brain magnetic resonance imaging measures included: T(1)-, T(2)- and gadolinium contrast-enhancing volumes and the T(2)-lesion volume relative magnetization transfer ratio, global and tissue specific white and grey matter brain atrophy and normal appearing grey and white matter magnetization transfer ratio. Regression analyses were employed for magnetic resonance imaging measures. The paediatric onset multiple sclerosis-C (n = 17) and adult onset multiple sclerosis-1 (n = 81) groups had mean disease duration values of 2.7 +/- standard deviation 2.0 and 2.6 +/- 1.1 years, respectively. The paediatric onset multiple sclerosis-A group (n = 33) and adult onset multiple sclerosis-2 group (n = 300) had mean disease durations of 20 +/- standard deviation 10.9 and 20 +/- 9.3 years, respectively. In regression analysis, the T(2)- lesion volume of the paediatric onset multiple sclerosis-C and adult onset multiple sclerosis-1 groups were similar but there was a trend toward higher T(1)- lesion volume (P = 0.028) in the paediatric onset group. The brain parenchymal fraction and grey matter fraction in the paediatric-onset multiple sclerosis-C group were higher than those for the adult onset multiple sclerosis-1 group (both P < 0.001). The frequency of progressive multiple sclerosis in the paediatric onset multiple sclerosis-A group (27.3%) trended lower (odds ratio = 0.43, P = 0.042) than that in the adult onset multiple sclerosis-2 group (46.3%). The Expanded Disability Status Scale (median; inter-quartile range) in the paediatric onset multiple sclerosis-A group (2.25; 2.5) trended lower (P = 0.058) compared with the adult onset multiple sclerosis-2 group (3.5; 4.0). There was a trend toward lower magnetization transfer ratio values in T(2)-lesions, normal appearing grey matter and normal appearing white matter and higher grey matter fraction in the paediatric onset multiple sclerosis-A group compared with the adult onset multiple sclerosis-2 group. There was no evidence for differences on T(2)-lesion volume, T(1)-lesion volume, brain parenchymal fraction or white matter fraction. Paediatric-onset multiple sclerosis is characterized by a significant disease burden both early and later in the disease course. Despite this, disability is slower to accrue in paediatric onset multiple sclerosis than adult onset multiple sclerosis.

Entities:  

Mesh:

Year:  2009        PMID: 19892770     DOI: 10.1093/brain/awp278

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  40 in total

1.  Multiple sclerosis: Which MRI findings predict MS development in children?

Authors:  E Ann Yeh
Journal:  Nat Rev Neurol       Date:  2012-02-28       Impact factor: 42.937

Review 2.  First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Authors:  Jessica Johnston; Tsz-Yin So
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

3.  Unusual patient with multiple sclerosis and shunt-responsive normal-pressure hydrocephalus.

Authors:  O Algin; O Taskapilioglu; B Hakyemez; M Parlak
Journal:  Clin Neuroradiol       Date:  2011-04-02       Impact factor: 3.649

Review 4.  Therapies for multiple sclerosis: considerations in the pediatric patient.

Authors:  Brenda Banwell; Amit Bar-Or; Gavin Giovannoni; Russell C Dale; Marc Tardieu
Journal:  Nat Rev Neurol       Date:  2011-01-11       Impact factor: 42.937

Review 5.  Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.

Authors:  Amy Waldman; Angelo Ghezzi; Amit Bar-Or; Yann Mikaeloff; Marc Tardieu; Brenda Banwell
Journal:  Lancet Neurol       Date:  2014-09       Impact factor: 44.182

6.  Tract-based spatial statistics analysis of diffusion-tensor imaging data in pediatric- and adult-onset multiple sclerosis.

Authors:  Rachel Aliotta; Jennifer L Cox; Katelyn Donohue; Bianca Weinstock-Guttman; E Ann Yeh; Paul Polak; Michael G Dwyer; Robert Zivadinov
Journal:  Hum Brain Mapp       Date:  2012-08-30       Impact factor: 5.038

7.  The impact of lesion in-painting and registration methods on voxel-based morphometry in detecting regional cerebral gray matter atrophy in multiple sclerosis.

Authors:  A Ceccarelli; J S Jackson; S Tauhid; A Arora; J Gorky; E Dell'Oglio; A Bakshi; T Chitnis; S J Khoury; H L Weiner; C R G Guttmann; R Bakshi; M Neema
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-29       Impact factor: 3.825

8.  Iron deposition on SWI-filtered phase in the subcortical deep gray matter of patients with clinically isolated syndrome may precede structure-specific atrophy.

Authors:  J Hagemeier; B Weinstock-Guttman; N Bergsland; M Heininen-Brown; E Carl; C Kennedy; C Magnano; D Hojnacki; M G Dwyer; R Zivadinov
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-29       Impact factor: 3.825

Review 9.  Disease-modifying therapy of pediatric multiple sclerosis.

Authors:  Tanuja Chitnis
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 10.  Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.

Authors:  J Nicholas Brenton; Brenda L Banwell
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.